

for FDA's Agricultural Biotechnology Education and Outreach Initiative.

III. Participating in the Public Meeting

Registration: To register for a public meeting, please include your name, title, firm name, address, and phone and fax numbers in your registration information and send to: Simone Katz, Strategic Results, 101 Lakeforest Blvd., Suite 390, Gaithersburg, MD 20877, 240-449-8427, Fax: 240-641-9042, email: simone.katz@strategicresults.com. You can register for one or both meetings.

Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public meeting must register by October 30, 2017, for the Charlotte, NC, meeting and must register by November 6, 2017, for the San Francisco, CA, meeting. Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted.

If you need special accommodations due to a disability, please contact Simone Katz, Strategic Results, 101 Lakeforest Blvd., Suite 390, Gaithersburg, MD 20877, 240-449-8427,

Fax: 240-641-9042, email: simone.katz@strategicresults.com no later than October 20, 2017, for the Charlotte, NC, meeting and no later than October 27, 2017, for the San Francisco, CA, meeting.

Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by October 24, 2017, for the meeting in Charlotte, NC, and by November 1, 2017, for the meeting in San Francisco, CA. All requests to make oral presentations must be received by October 20, 2017, for the meeting in Charlotte, NC, and by October 27, 2017, for the meeting in San Francisco, CA.

Streaming Webcast of the Public Meeting: Each public meeting will also be webcast. Individuals who wish to participate by webcast are asked to preregister at: <https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm>

If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/go/connectpro_overview. FDA has verified the Web site addresses in this document, as of the date this document publishes in the **Federal Register**, but Web sites are subject to change over time.

Transcripts: Please be advised that as soon as a transcript of each public meeting is available, it will be accessible at <https://www.regulations.gov>. It may be viewed at the Dockets Management Staff (see **ADDRESSES**). A link to the transcript will also be available on the internet at <https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm>.

Other Issues for Consideration: A summary of key information on participating in a meeting follows:

TABLE 1—INFORMATION ON PARTICIPATION IN THE MEETING

Date	Address	Preregister	Electronic address	Request to make an oral presentation	Special accommodations	Submit either electronic or written comments
November 7, 2017, from 8:30 a.m. to 1 p.m. EST.	Omni Charlotte Hotel, 132 E Trade St., Charlotte, NC 28202.	October 30, 2017: Closing date for registration.	Please preregister at https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm .	October 20, 2017.	October 20, 2017: Closing date to request special accommodations due to a disability.	Submit Comments by November 17, 2017, to: https://www.regulations.gov , or Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
November 14, 2017, from 8:30 a.m. to 1 p.m. PST.	San Francisco Marriott Marquis, 780 Mission St., San Francisco, CA 94103.	November 6, 2017: Closing date for registration.	Please preregister at https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm .	October 27, 2017.	October 27, 2017: closing date to request special accommodations due to a disability.	Same as above.

You may also register via email, mail, or fax. Please include your name, title, firm name, address, and phone and Fax numbers in your registration information and send to: Simone Katz, Strategic Results, 101 Lakeforest Blvd., Suite 390, Gaithersburg, MD 20877, 240-449-8427, Fax: 240-641-9042, email: simone.katz@strategicresults.com.

Individuals who wish to participate by webcast are asked to preregister at: <https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm>.

[WorkshopsMeetingsConferences/default.htm](https://www.fda.gov/Food/NewsEvents/WorkshopsMeetingsConferences/default.htm).

Dated: October 6, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
 [FR Doc. 2017-22172 Filed 10-12-17; 8:45 am]
BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-5953]

Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. The meeting will be open to the public.

DATES: The meeting will be held on December 12, 2017, from 8 a.m. to 6 p.m.

ADDRESSES: Hilton Washington DC North/Gaithersburg, salons A, B, C, and D, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone number is 301-977-8900.

FOR FURTHER INFORMATION CONTACT: Sara J. Anderson, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G616, Silver Spring, MD 20993-0002, 301-796-7047, Sara.Anderson@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at <https://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

SUPPLEMENTARY INFORMATION:

Agenda: On December 12, 2017, the committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the Barricaid Anular Closure Device by Intrinsic Therapeutics. The proposed Indication for Use, as stated in the PMA, is as follows: The Barricaid is intended to be implanted following a limited discectomy, to prevent reherniation and the recurrence of pain or dysfunction. The Barricaid is indicated for patients with radiculopathy (with or without back pain), a posterior or posterolateral herniation, characterized by radiographic confirmation of neural compression using magnetic resonance imaging, and a large anular defect (e.g., between 4-6 mm tall and between 6-12 mm wide) post discectomy, at one level between L4 and S1.

FDA intends to make background material available to the public no later

than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before December 1, 2017. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 3, 2017. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 9, 2017.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact AnnMarie Williams at Annmarie.Williams@fda.hhs.gov or 301-796-5966 at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 6, 2017.

Anna K. Abram,

Deputy Commissioner for Policy, Planning, Legislation, and Analysis.

[FR Doc. 2017-22174 Filed 10-12-17; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows.

Derivatives of Docosahexaenoyl ethanolamide (DEA) for Neurogenesis

The invention pertains to derivatives of docosahexaenoyl ethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3